StreetInsider.com News Articles

Form 8-K SUPERNUS PHARMACEUTICALS For: Jul 22

Wed, 22 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260722/26802592.html

Form 8-K SUPERNUS PHARMACEUTICALS For: Jul 22

Wed, 22 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260722/26802592.html

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Wed, 22 Jul 2026 17:05:00 -0400

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss these results. Following management’s prepared remarks and discussion of business results,

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Wed, 22 Jul 2026 17:05:00 -0400

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Wed, 22 Jul 2026 17:05:00 -0400

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Wed, 22 Jul 2026 17:05:00 -0400

Supernus Pharma (SUPN) call put ratio 1 call to 4 puts

Thu, 16 Jul 2026 06:14:36 -0400

Supernus Pharma (NASDAQ: SUPN) 30-day call option implied volatility is 54; compared to its 52-week range of 30 to 67. Call put ratio 1 call to 4 puts.

Supernus marks five years of Qelbree ADHD drug with 3M prescriptions

Tue, 14 Jul 2026 08:30:39 -0400

Supernus Pharmaceuticals (Nasdaq: SUPN) marked the five-year anniversary of the FDA approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder, noting approximately 3 million total prescriptions filled since the drug's launch, including over 1 million in 2025 alone.

Qelbree was first approved in April 2021 for pediatric patients ages 6 to 17, and received an expanded FDA indication in April 2022 for adults 18 and older. According to the company, the adult approval marked the first non-stimulant ADHD treatment option for that age group in two decades.

In January 2025, the FDA approved labeling updates for Qelbree to include additional pharmacodynamic data,

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

Tue, 14 Jul 2026 08:30:00 -0400

Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT_2C) pharmacodynamics approved in its FDA product labeling.
Qelbree has provided convenient 24-hour medication exposure for patients with ADHD ages 6 years and older, with approximately 3 million prescriptions filled since launch.
As a non-controlled treatment option, Qelbree has no evidence of abuse potential and is supported by years of clinical and real-world data.

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

Tue, 14 Jul 2026 08:30:00 -0400

Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT_2C) pharmacodynamics approved in its FDA product labeling.
Qelbree has provided convenient 24-hour medication exposure for patients with ADHD ages 6 years and older, with approximately 3 million prescriptions filled since launch.
As a non-controlled treatment option, Qelbree has no evidence of abuse potential and is supported by years of clinical and real-world data.

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing

Form S-8 SUPERNUS PHARMACEUTICALS

Mon, 22 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260622/26673786.html

Form S-8 SUPERNUS PHARMACEUTICALS

Mon, 22 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260622/26673786.html

Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26666944.html

Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18

Thu, 18 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26666944.html

Supernus names MERGE as agency of record for its CNS portfolio

Wed, 17 Jun 2026 10:15:10 -0400

Supernus Pharmaceuticals (Nasdaq: SUPN) has expanded its partnership with marketing and technology agency MERGE, naming the firm as its Agency of Record for its central nervous system portfolio, according to a press release.

The agreement extends MERGE's existing relationship with Supernus beyond the company's Parkinson's disease portfolio to include QELBREE® (viloxazine extended-release capsules), a non-stimulant treatment for ADHD. MERGE will also assume oversight of Supernus' digital ecosystem, including website development and CRM operations.

MERGE will continue supporting Supernus' Parkinson's disease brands: APOKYN® (apomorphine hydrochloride), GOCOVRI® (amantadine extended-release capsules), and ONAPGO™ (apomorphine hydrochloride). The agency will lead omnichannel marketing strategy across the portfolio

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Wed, 17 Jun 2026 10:15:00 -0400

Engagement Includes CNS Portfolio and Digital Ecosystem

CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- MERGE announces its selection as the Agency of Record (AOR) for Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dynamic biopharmaceutical company dedicated to developing cutting-edge treatments for central nervous system (CNS) diseases.

With AI rapidly reshaping the medical marketing landscape, Supernus is moving to embrace a future where human creativity meets the science of data and technology. This expanded partnership, which unifies Supernus’ digital marketing and technology platforms, is designed to leverage MERGE's core philosophy—building a blueprint for human-AI collaboration—to redefine healthcare

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Wed, 17 Jun 2026 10:15:00 -0400

Engagement Includes CNS Portfolio and Digital Ecosystem

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Supernus Pharmaceuticals to Participate in June Investor Conferences

Wed, 27 May 2026 16:30:00 -0400

2026 Jefferies Global Healthcare Conference

Date:
Fireside chat:
Place:
Webcast Link:

Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Wed, 20 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26529021.html

Form 8-K SUPERNUS PHARMACEUTICALS For: May 17

Wed, 20 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260520/26529021.html

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

Investors interested in arranging a meeting with company management during the conference should contact the Bank of

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

Wed, 06 May 2026 17:00:00 -0400

Investors interested in arranging a meeting with company management during the conference should contact the Bank of